
Sun Pharma gets FDA approval for acne treatment
pharmafile | August 21, 2015 | News story | Medical Communications, Research and Development, Sales and Marketing | Sun Pharma. acne treatments, drug approvals
The FDA has approved Sun Pharma’s new acne treatment, Ximino.
The Ximino (minocycline hydrochloride) extended-release capsules, which will be available in 45 mg, 90 mg and 135 mg dosages, are available for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 12 years and above.
Sun Pharma stocks rose more than 3% on the back of the news of the approval, with analysts suggesting the drug may add between $50 and $80 million to the company’s annual sales.
Sun – India’s largest pharma company – said the approval further strengthens its branded dermatology portfolio in the US, which is the largest market in the world for acne, with some 50 million people who live with the condition.
The company has focused on dermatological products since it completed a $4 billion acquisition of fellow Indian firm Ranbaxy Laboratories in February this year.
Ximino is expected to be available for patients during the fourth quarter of 2015.
Joel Levy
Related Content

FDA steps up 2018 drug approvals by 11% on previous year
The FDA continues to excel in the ground it covers as it emerges that the …

EMA approves more new active substances in 2018, but total recommendations fall
2018 was a strong year for European approvals according to the EMA; the regulator has …

China to accelerate drug approvals with overseas trial data
In a bid to speed up access to medicines for patients, China has revealed it …






